US Patent

US11389436 — Methods of treating fabry patients having renal impairment

Method of Use · Assigned to Amicus Therapeutics Inc · Expires 2038-05-30 · 12y remaining

Vulnerability score 53/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods for treating Fabry disease in patients with certain genetic mutations, using migalastat hydrochloride administered every other day.

USPTO Abstract

Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in Î±-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.

Drugs covered by this patent

migalastat-hydrochloride (MIGALASTAT HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2371`	—	migalastat-hydrochloride

Patent Metadata

Patent number: US11389436
Jurisdiction: US
Classification: Method of Use
Expires: 2038-05-30
Drug substance claim: No
Drug product claim: No
Assignee: Amicus Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.